<DOC>
	<DOCNO>NCT00217282</DOCNO>
	<brief_summary>The combination oxaliplatin gemcitabine proven activity advance non-small cell lung cancer ( NSCLC ) . Due favorable toxicity profile , combination optimal add new agent . Bevacizumab anti-VEGF monoclonal antibody also show favorable result advance NSCLC . This study add bevacizumab oxaliplatin gemcitabine first line treatment patient Stage IIIB IV NSCLC .</brief_summary>
	<brief_title>Study Oxaliplatin Gemcitabine With Without Bevacizumab Treat Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>STUDY OBJECTIVES : Primary : To determine overall time progression combination regimen Gemcitabine , Oxaliplatin Bevacizumab first-line treatment patient Stage IIIB IV non-small cell lung cancer . Secondary - To determine overall response rate - To determine overall survival . - To determine toxicity Gemcitabine , Oxaliplatin give combination Bevacizumab ELIGIBILITY CRITERIA 1 . Patients must histologically cytologically confirm non-small cell lung cancer EXCEPT squamous cell carcinoma . Mixed tumor categorize predominant cell type unless small cell element present case patient ineligible . Cytologic histologic element establish metastatic tumor aspirate biopsy . 2 . Patients must advance NSCLC ( Stage IIIB malignant pleural effusion Stage IV recurrent disease ) . 3 . Patients must measurable disease ( defined Section 13.0 ) . 4 . ECOG performance status 0 1 . 5 . Patients must know CNS metastasis . Brain imaging require within 4 week prior study entry . 6 . No prior systemic treatment advance NSCLC permit . Prior treatment early-stage disease ( adjuvant ) locally-advanced Stage III disease allow complete least 12 month prior registration . 7 . Required laboratory value ( obtain 2 week prior registration ) : 7.1 ANC &gt; 1500/mm³ . 7.2 Platelets &gt; 100,000/mm³ . 7.3 Total Bilirubin &lt; 1.5 mg/dl . 7.4 Transaminases &lt; 5 x ULN . 8 . Patients must adequate renal function determine follow test within 2 week prior registration . 8.1 Serum creatinine less equal 1.5 x upper limit normal ( ULN ) , AND Urinalysis &lt; 1+ protein* * Patients discover &gt; 1+ proteinuria baseline must undergo 24-hour urine collection . This must adequate collection must demonstrate &lt; 1g protein/24 hr allow participation study . 9 . Patients must 18 year old . 10 . Pregnant lactate woman exclude study agent use study may teratogenic fetus information excretion agent metabolites breast milk . A negative urine serum pregnancy test require woman childbearing potential . 11 . Women childbearing potential sexually active male must agree use accepted effective method contraception ( hormonal barrier method , abstinence ) prior study entry duration study . 12 . Patients treated radiation therapy must adverse event therapy resolve grade 2 less follow completion treatment . 13 . Patients must ongoing active infection , symptomatic congestive heart failure , cerebrovascular accident within 12 month , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 14 . Patients must deep vein thrombosis pulmonary embolus within one year registration ongoing need full-dose oral parenteral anticoagulation . Low dose coumadin ( 1mg ) maintenance catheter patency daily prophylactic aspirin allow . 15 . Patients history hypertension must well-controlled ( define blood pressure &gt; 160 mmHg systolic and/or &gt; 110 mmHg diastolic ) stable regimen anti-hypertensive therapy . 16 . Patients must serious non-healing wound ulcer , bone fracture , major surgical procedure within 3 week prior start treatment . 17 . Patients history gross hemoptysis ( define bright red blood ½ teaspoon ) exclude trial 18 . No prior malignancy allow except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient disease-free five year TREATMENT PLAN Gemcitabine 1000mg/m2 IV 30 minute , day 1 8 follow Oxaliplatin 130mg/m2 IV 2 hour day 1 follow Bevacizumab 15 mg/kg IV 90* minute , day 1 Cycles q 3 week x 4 cycle One cycle equal 3 week . Patients re-evaluated every 2 cycle . If CR , PR SD , patient continue treatment four cycle progression unacceptable toxicity . Patients achieve CR , PR , SD 4 cycle continue Bevacizumab maintenance : Bevacizumab 15 mg/kg IV q 3 week relapse/progression</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Confirmed nonsmall cell lung cancer , EXCEPT squamous cell cancer Stage IIIB IV disease ECOG PS 01 No prior treatment No brain metastasis Must measurable disease Deep vein thrombose pulmonary embolus within 1 year History gross hemoptysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>